PPIB and ventilator-associated pneumonia: These novel β-lactam-β-lactamase inhibitor combinations are effective against MDR P. aeruginosa and have been approved for the treatment of complicated intra-abdominal infections, urinary tract infections, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) [6].